US Bancorp DE Has $577,000 Stock Position in Enovis Corporation $ENOV

US Bancorp DE lowered its position in shares of Enovis Corporation (NYSE:ENOV) by 3.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,408 shares of the company’s stock after selling 623 shares during the quarter. US Bancorp DE’s holdings in Enovis were worth $577,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ENOV. Farther Finance Advisors LLC lifted its holdings in shares of Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares in the last quarter. GAMMA Investing LLC raised its stake in Enovis by 144.8% in the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock valued at $45,000 after purchasing an additional 692 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Enovis by 6.7% in the first quarter. Janney Montgomery Scott LLC now owns 21,782 shares of the company’s stock valued at $832,000 after purchasing an additional 1,366 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Enovis by 394.4% in the first quarter. State of Alaska Department of Revenue now owns 31,504 shares of the company’s stock valued at $1,203,000 after purchasing an additional 25,132 shares in the last quarter. Finally, Stonegate Investment Group LLC acquired a new position in Enovis in the first quarter valued at about $237,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the subject of a number of analyst reports. Canaccord Genuity Group dropped their price target on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Wells Fargo & Company dropped their price target on Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Evercore ISI dropped their price target on Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Finally, UBS Group decreased their target price on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Insider Buying and Selling at Enovis

In other Enovis news, CEO Damien Mcdonald purchased 6,457 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were purchased at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the purchase, the chief executive officer owned 102,753 shares in the company, valued at $3,182,260.41. This represents a 6.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Bradley J. Tandy purchased 3,200 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was acquired at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the purchase, the senior vice president owned 43,515 shares of the company’s stock, valued at approximately $1,366,806.15. This trade represents a 7.94% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 12,157 shares of company stock valued at $374,760. 2.70% of the stock is currently owned by company insiders.

Enovis Price Performance

Enovis stock opened at $31.41 on Monday. The stock’s 50 day moving average is $30.87 and its 200 day moving average is $31.53. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The firm has a market cap of $1.80 billion, a P/E ratio of -2.20 and a beta of 1.69. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Monday, January 8th. The company reported $0.59 EPS for the quarter. The company had revenue of $383.81 million for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. As a group, research analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.